GUAIFENESIN- guaifenesin tablet, extended release GRANULES PHARMACEUTICALS INC.

Guaifenesin Extended-Release Tablets 600mg and 1200mg

ACTIVE INGREDIENT(S)

Guaifenesin 600 mg (for 600mg)

PURPOSE

Expectorant

USE(S)

 helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive

WARNINGS

Do not use

for children under 12 years of age

ASK A DOCTOR BEFORE USE IF YOU HAVE

- persistent or chronic cough such as occurs with smoking, asthma, chronic bronchitis, or emphysema
- cough accompanied by too much phlegm (mucus)

STOP USE AND ASK DOCTOR IF

• cough lasts more than 7 days, comes back, or occurs with fever, rash, or persistent headache. These could be signs of a serious illness.

If pregnant or breast-feeding,

ask a health professional before use.

KEEP OUT OF REACH OF CHILDREN

In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222)

DIRECTIONS

do not crush, chew, or break tablet

- take with a full glass of water
- this product can be administered without regard for timing of meals
- adults and children 12 years of age and over: 1 or 2 tablets every 12 hours. Do not exceed 4 tablets in 24 hours(For 600mg)
- children under 12 years of age: do not use

OTHER INFORMATION

- do not use if foil inner seal is broken or missing.
- store between 20-25°C (68-77°F)

INACTIVE INGREDIENTS


carbomer homopolymer type B; hypromellos, magnesium stearate, microcrystalline cellulose, sodium starch glycolate

QUESTIONS OR COMMENTS

Contact 1-877-770-3183 Mon-Fri 8:00 AM EST to 5:00 PM PST.

All trademarks are property of their respective owners.MUCINEX is the registered trademark of Reckitt Benckiser LLC.

PRINCIPAL DISPLAY PANEL



guaifenesin tablet, extended release Product Information Product Type HUMAN OTC DRUG Item Code (Source) NDC:70010-199

Route of Administration

ORAL

Active Ingredient/Active Moiety

| 3 • • • • • • • • • • • • • • • • • • • | | |
|--|--------------------------|----------|
| Ingredient Name | Basis of Strength | Strength |
| GUAIFENESIN (UNII: 495W7451VQ) (GUAIFENESIN - UNII:495W7451VQ) | GUAIFENESIN | 600 mg |

Inactive Ingredients

| Ingredient Name | Strength |
|--|----------|
| SODIUM STARCH GLYCOLATE TYPE A (UNII: H8AV0SQX4D) | |
| MAGNESIUM STEARATE (UNII: 70097M6I30) | |
| CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) (UNII: Z135WT9208) | |
| MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U) | |
| HYPROMELLOSE 2910 (5 MPA.S) (UNII: R75537T0T4) | |
| HYPROMELLOSE 2910 (10000 MPA.S) (UNII: 0HO1H52958) | |

Product Characteristics

| | ounce characteristics | | |
|----------|-----------------------|--------------|----------|
| Color | white | Score | no score |
| Shape | OVAL | Size | 16mm |
| Flavor | | Imprint Code | G;600 |
| Contains | | | |

Packaging

| # | Item Code | Package Description | Marketing Start Date | Marketing End Date |
|---|----------------------|--|-------------------------|-----------------------|
| | NDC:70010-199- 05 | 500 in 1 BOTTLE; Type 0: Not a Combination Product | 08/19/2022 | |

Marketing Information

| · · · · · · · · · · · · · · · · · · · | | | | | | |
|---------------------------------------|---|-------------------------|-----------------------|--|--|--|
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date | | | |
| ANDA | ANDA213420 | 08/19/2022 | | | | |
| | | | | | | |

Labeler - GRANULES PHARMACEUTICALS INC. (079825711)

Revised: 1/2023 GRANULES PHARMACEUTICALS INC.